UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, $40 PT
Posted on January 04, 2013 at 08:38 AM EST
In a report published Friday, Bank of America Merrill Lynch initiated coverage on AbbVie (NYSE: ABBV ) with a Buy rating and $40.00 price target. BofA Merrill Lynch noted, “ABBV is unique among the US Major Pharma companies given its significant product concentration (45% of 2011 revenues were generated by